Kyowa Kirin is continuing to monitor the COVID-19 outbreak. Learn More

Dosing modifications for adverse reactions1

Dermatologic toxicity

  • Monitor patients for rash throughout the treatment course
  • Rash (drug eruption) may be visually indistinguishable from disease progression
  • Consider skin biopsy to help make a differential diagnosis
Table of dosing modification recommendations for dermatologic toxicity (by grade)

Infusion reactions

Common signs of infusion reactions

chills | nausea | fever | tachycardia | rigors | headache | vomiting

Table of dosing modification recommendations for infusion reaction (by grade)

Use in special populations

Pharmacokinetics

No clinically significant changes in the pharmacokinetics of POTELIGEO were observed based on age, renal impairment, or mild/moderate hepatic impairment. As a result, no corresponding dose modifications are required.

Geriatric use

  • In MAVORIC, 51% of patients treated with POTELIGEO were 65 years of age or older (range: 25 to 101)
  • No overall differences in effectiveness were observed between patients 65 or older and younger patients
  • Patients 65 or older had a greater number of grade 3 or higher adverse reactions than patients under 65, but the difference was not statistically significant

For more information on dosing, see the POTELIGEO Dosing and Administration Guide

POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.

Important Safety Information

SEE LESS